SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-064230
Filing Date
2022-05-24
Accepted
2022-05-24 16:12:01
Documents
12
Period of Report
2022-05-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2214825d1_8k.htm   iXBRL 8-K 31349
  Complete submission text file 0001104659-22-064230.txt   205134

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA casi-20220523.xsd EX-101.SCH 3033
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20220523_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20220523_pre.xml EX-101.PRE 22595
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2214825d1_8k_htm.xml XML 3586
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20713 | Film No.: 22956760
SIC: 2836 Biological Products, (No Diagnostic Substances)